Medicenna Therapeutics Appoints New Chief Medical Officer

Dr. Nageatte Ibrahim joins the biotech company to lead clinical development.

Apr. 9, 2026 at 1:44pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image of a molecular structure representing a cancer cell, glowing against a dark background, conceptually illustrating the challenges of cancer drug development.Medicenna's new Chief Medical Officer will guide the company's efforts to develop cutting-edge cancer treatments through rigorous clinical trials.Houston Today

Medicenna Therapeutics, a biopharmaceutical company focused on developing immunotherapies, has appointed Dr. Nageatte Ibrahim as its new Chief Medical Officer. Dr. Ibrahim will lead the company's clinical development efforts as it advances its pipeline of cancer treatments.

Why it matters

Medicenna's appointment of an experienced medical leader like Dr. Ibrahim signals the company's commitment to accelerating its drug candidates through clinical trials and towards regulatory approval. As a biotech focused on innovative cancer therapies, Medicenna's success could lead to new treatment options for patients.

The details

In his new role, Dr. Ibrahim will be responsible for overseeing all of Medicenna's clinical development programs, including the company's lead candidate MDNA55, an investigational IL-4 guided missile that is currently in Phase 2b trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer.

  • Medicenna announced Dr. Ibrahim's appointment on April 9, 2026.

The players

Medicenna Therapeutics Corp.

A biopharmaceutical company focused on developing immunotherapies for cancer treatment.

Dr. Nageatte Ibrahim

An experienced medical leader who has joined Medicenna as its new Chief Medical Officer to oversee the company's clinical development programs.

Got photos? Submit your photos here. ›

What they’re saying

“We are delighted to welcome Dr. Ibrahim to the Medicenna team. His extensive experience in oncology drug development will be invaluable as we advance our pipeline of novel immunotherapies.”

— Fahar Merchant, President and CEO of Medicenna

The takeaway

Medicenna's appointment of an experienced medical leader like Dr. Ibrahim underscores the company's commitment to developing innovative cancer therapies and advancing its pipeline of immunotherapy candidates through clinical trials.